应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
NKTR 内克塔治疗
盘前交易 11-18 04:19:21 EST
35.91
-0.53
-1.45%
最高
36.50
最低
35.41
成交量
73.12万
今开
36.31
昨收
36.44
日振幅
2.99%
总市值
12.26亿
流通市值
12.10亿
总股本
3,414万
成交额
2,630万
换手率
2.17%
流通股本
3,370万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
财报前瞻 | 内克塔治疗本季度营收预计小幅增长,机构观点偏审慎
财报Agent · 11-05
财报前瞻 | 内克塔治疗本季度营收预计小幅增长,机构观点偏审慎
异动解读|内克塔治疗盘中下跌19.63%,报48.66美元
行情直击 · 10-02
异动解读|内克塔治疗盘中下跌19.63%,报48.66美元
内克塔治疗(NKTR)盘前涨5% 诉礼来案胜诉 陪审团裁定赔偿9000万美元及利息
金吾财讯 · 09-25
内克塔治疗(NKTR)盘前涨5% 诉礼来案胜诉 陪审团裁定赔偿9000万美元及利息
内克塔治疗宣布自2026年9月8日起进入静默期,直至Rezolve-Aa二期B阶段研究数据公布——源自SEC申报文件
美股速递 · 09-09
内克塔治疗宣布自2026年9月8日起进入静默期,直至Rezolve-Aa二期B阶段研究数据公布——源自SEC申报文件
内克塔治疗宣布Rezolve-Ad研究达标:Rezpegaldesleukin 24 μg/kg每两周方案全面实现主要及关键次要终点
美股速递 · 08-25
内克塔治疗宣布Rezolve-Ad研究达标:Rezpegaldesleukin 24 μg/kg每两周方案全面实现主要及关键次要终点
财报前瞻|内克塔治疗本季度营收预计小幅下滑,看空观点占优
财报Agent · 08-06
财报前瞻|内克塔治疗本季度营收预计小幅下滑,看空观点占优
内克塔治疗:三期关键顶线数据预计2028年中出炉,生物制品许可申请目标锁定2029年
美股速递 · 07-21
内克塔治疗:三期关键顶线数据预计2028年中出炉,生物制品许可申请目标锁定2029年
内克塔治疗启动Zenith AD三期项目,评估新型调节性T细胞生物制剂Rezpegaldesleukin用于中重度特应性皮炎
美股速递 · 07-21
内克塔治疗启动Zenith AD三期项目,评估新型调节性T细胞生物制剂Rezpegaldesleukin用于中重度特应性皮炎
内克塔治疗盘中异动 股价大跌5.25%
市场透视 · 2025-03-10
内克塔治疗盘中异动 股价大跌5.25%
内克塔治疗盘中异动 股价大涨5.06%报0.901美元
市场透视 · 2025-03-07
内克塔治疗盘中异动 股价大涨5.06%报0.901美元
内克塔治疗盘中异动 股价大涨5.45%报0.846美元
市场透视 · 2025-03-05
内克塔治疗盘中异动 股价大涨5.45%报0.846美元
内克塔治疗盘中异动 快速拉升5.15%
市场透视 · 2025-03-01
内克塔治疗盘中异动 快速拉升5.15%
内克塔治疗盘中异动 急速上涨6.36%报0.830美元
市场透视 · 2025-02-27
内克塔治疗盘中异动 急速上涨6.36%报0.830美元
内克塔治疗盘中异动 早盘股价大跌5.00%报0.827美元
市场透视 · 2025-02-26
内克塔治疗盘中异动 早盘股价大跌5.00%报0.827美元
内克塔治疗盘中异动 早盘急速下跌5.11%
市场透视 · 2025-02-25
内克塔治疗盘中异动 早盘急速下跌5.11%
内克塔治疗盘中异动 快速下跌5.39%
市场透视 · 2025-02-24
内克塔治疗盘中异动 快速下跌5.39%
内克塔治疗盘中异动 早盘快速下挫5.19%
市场透视 · 2025-02-19
内克塔治疗盘中异动 早盘快速下挫5.19%
内克塔治疗盘中异动 股价大涨5.84%
市场透视 · 2025-02-19
内克塔治疗盘中异动 股价大涨5.84%
内克塔治疗盘中异动 急速上涨5.38%报0.940美元
市场透视 · 2025-02-14
内克塔治疗盘中异动 急速上涨5.38%报0.940美元
内克塔治疗盘中异动 早盘急速拉升9.37%
市场透视 · 2025-02-13
内克塔治疗盘中异动 早盘急速拉升9.37%
加载更多
公司概况
公司名称:
内克塔治疗
所属市场:
NASDAQ
上市日期:
--
主营业务:
Nektar Therapeutics于1990年在加州成立,并于1998年重新在特拉华州注册。该公司是一家临床阶段、研究型药物发现生物制药公司,专注于发现和开发免疫治疗领域的创新药物。在这个不断增长的领域内,该公司致力于创造新的免疫调节剂,选择性地诱导、放大、减弱或阻止免疫反应,以达到预期的治疗效果。
发行价格:
--
{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"内克塔治疗","latestPrice":35.91,"timestamp":1794949200000,"preClose":36.44,"halted":0,"volume":731152,"delay":0,"changeRate":-0.014544456641053818,"floatShares":33695095,"shares":34142994,"eps":-6.307625,"marketStatus":"盘前交易","change":-0.53,"latestTime":"11-18 04:19:21 EST","open":36.31,"high":36.5,"low":35.41,"amount":26304898.977616,"amplitude":0.029912,"askPrice":39.58,"askSize":100,"bidPrice":35.16,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-6.307625,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795012200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":35.91,"postHourTrading":{"tag":"盘后","latestPrice":36.66,"preClose":35.91,"latestTime":"19:30 EST","volume":49196,"amount":1767240.1174,"timestamp":1794961801645,"change":0.75,"changeRate":0.020886,"amplitude":0.024784},"volumeRatio":1.1229874900016863,"impliedVol":0.8661,"impliedVolPercentile":0.68},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"1159082355","title":"财报前瞻 | 内克塔治疗本季度营收预计小幅增长,机构观点偏审慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1159082355","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159082355?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:26","pubTimestamp":1793841999,"startTime":"0","endTime":"0","summary":"内克塔治疗将于2026年11月12日发布最新季度财报,市场关注费用端收缩与合作收入节奏对利润曲线的影响。市场一致预期显示,本季度内克塔治疗营收预计为1,027.37万美元,同比增2.24%;预计毛利率为100.00%;预计息税前利润为-6,747.79万美元,同比下降-72.34%;预计调整后每股收益为-2.07元,同比改善22.91%。公司收入以合作与版税为主,毛利率保持在100.00%,本季度营收预测小幅增长主要取决于合作项目的里程碑确认节奏与版税安排的现金化进度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | 内克塔治疗本季度营收预计小幅增长,机构观点偏审慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101597430","title":"异动解读|内克塔治疗盘中下跌19.63%,报48.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101597430","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101597430?lang=zh_cn&edition=full","pubTime":"2026-10-02 02:39","pubTimestamp":1790879982,"startTime":"0","endTime":"0","summary":"10月1日,内克塔治疗盘中下跌19.63%,报48.66美元/股,成交额2.06亿美元。内克塔治疗所在的制药行业中,个股普遍承压,其中礼来跌0.77%,强生跌2.0%,默沙东跌1.03%,Liquidia Technologies跌11.63%,辉瑞跌1.21%。内克塔治疗是一家临床阶段研究型生物制药公司,专注于免疫治疗领域创新药物的发现和开发,致力于创造新的免疫调节剂以达到预期治疗效果。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670068442","title":"内克塔治疗(NKTR)盘前涨5% 诉礼来案胜诉 陪审团裁定赔偿9000万美元及利息","url":"https://stock-news.laohu8.com/highlight/detail?id=2670068442","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670068442?lang=zh_cn&edition=full","pubTime":"2026-09-25 19:34","pubTimestamp":1790336099,"startTime":"0","endTime":"0","summary":"金吾财讯 | 内克塔治疗(NKTR)盘前涨5.04%,报62.373美元。内克塔治疗公布,美国陪审团裁定礼来(LLY)在双方rezpegaldesleukin合作项目纠纷中,违反善意与公平交易默示契约,判决礼来向内克塔治疗支付9000万美元赔偿金并计付利息。本次陪审团裁决仍需经过庭审后续程序,最终判决结果存在被上诉的可能性。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/ZWJkNDM0ZDIxZGI0MmM2OTU5ZmFmYmIzNDdlN2ZlMTM1NjQzNTM3NDg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWJkNDM0ZDIxZGI0MmM2OTU5ZmFmYmIzNDdlN2ZlMTM1NjQzNTM3NDg=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306492","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0001KFT4U8.USD","LU2106854487.HKD","LU2471134796.USD","BK4007","RXL","LLY","LU0456855351.SGD","IE0004445015.USD","IE00B775H168.HKD","LU2087625088.SGD","LU2211815571.USD","LU1035775433.USD","LLYX","LU1868837136.USD","LU1023059063.AUD","LU2361044949.HKD","LU1868836591.USD","MHIP","CANC","LU1720051017.SGD","LU0256863902.USD","LU1804176565.USD","SG9999014914.USD","LU2168564065.EUR","LU1917777945.USD","LU0823434583.USD","IE00BN29S564.USD","LU0203201768.USD","LU0225283273.USD","OZEM","LU0354030438.USD","LU2552382058.USD","TMED","SGXZ99366536.SGD","LU0354030511.USD","LU1989771016.USD","LU2357305700.SGD","LU2552382215.SGD","LU0203202063.USD","LU1623119135.USD","LU2236285917.USD","LU0820561909.HKD","LU0889565916.HKD","LU1712237335.SGD","LU0234572021.USD","LU1868836757.USD","LU1280957306.USD","LU2237443978.SGD","LU0106261372.USD","LU1057294990.SGD","JDOC","LU2271345857.HKD","IE00BKPKM429.USD","LU1551013342.USD","LU1814569148.SGD","SG9999015952.SGD","IE00BFSS7M15.SGD","LU2417539215.USD","LU2360106947.USD","LU2168564222.USD","LU2361045086.USD","LU1988902786.USD","LU1548497426.USD","LU0238689110.USD","LU1093756325.SGD","LU2462591350.SGD","LU0289739699.SGD","LU1323610961.USD","LU2023250330.USD","LU1127390331.HKD","LU1629891620.HKD","IE00BFTCPJ56.SGD","IE00B1XK9C88.USD","LU0097036916.USD","LU1366192091.USD","LU0316494557.USD","IE0005OL40V9.USD","LU0345770308.USD","LU0787776722.HKD","SG9999017495.SGD","SGXZ51526630.SGD","LU0943347566.SGD","LU2756315318.SGD","LU2237443895.HKD","LU0320765059.SGD","LU0882574139.USD","LU0158827948.USD","LU0174119429.USD","LU1064131342.USD","LU1232071149.USD","IE00B2B36J28.USD","GDOC","LU0640476718.USD","LU2461242641.AUD","IE0004445239.USD","IE00BJT1NW94.SGD","LU2108987350.USD","LU2552382132.HKD","MEDI","IE00BK4W5L77.USD","IHE","BK4585","FHLC","LU2237443465.HKD","LU2750360641.GBP","LU2063271972.USD","PPH","IE00BJJMRZ35.SGD","LU2471134952.CNY","LU0786609619.USD","LU2491049909.HKD","BK4599","BK4588","IXJ","LU2112291526.USD","LU2468319806.SGD","LU0079474960.USD","LU2756315664.SGD","LU1691799644.USD","LU0353189680.USD","SGXZ31699556.SGD","LU2471134523.USD","LLII","ELIL","LU0471298777.SGD","LU1983299246.USD","LU2089984988.USD","LU0466842654.USD","MEDX","LU0882574055.USD","LU1974910355.USD","SG9999001176.USD","LU2237443549.SGD","LU1551013425.SGD","WDNA","AGNG","LU2111349929.HKD","BK4534","IE00BJLML261.HKD","LU0385154629.USD","LU1093756168.USD","LU2471134879.HKD","SG9999018857.SGD","LU0964807845.USD","LU0345770993.USD","LU1145028129.USD","LU1291159041.SGD","LU2361044865.SGD","LU2089284900.SGD","LU0122379950.USD","LU0158827781.USD","LU0417517546.SGD","IE00BWXC8680.SGD","LU2237443382.USD","LU2237443622.USD","IE0002141913.USD","NKTR","SG9999014898.SGD","SG9999015945.SGD","BK4581","LU0114720955.EUR","LU2168563687.JPY","LU2896262040.SGD","LU1979441026.SGD","SG9999013999.USD","LU2237438978.USD","LU0672654240.SGD","IE00BK4W5M84.HKD","LU0058720904.USD","ELIS","HRTS","LU2456880835.USD","SG9999014906.USD","LU0823434740.USD","SG9999015978.USD","SGXZ81514606.USD","TRUH","VHT","LU0266013472.USD","LU2023250504.SGD","LU2089283258.USD","SGXZ57979304.SGD","LU0109394709.USD","LU0094547139.USD","LU1061106388.HKD","LU1868836914.USD","LU2028103732.USD","SG9999001176.SGD","LU0323591593.USD","LU2168564495.EUR","LU2264538146.SGD","LU0320765992.SGD","SG9999015986.USD","IE00B4JS1V06.HKD","CURE","LU2491050071.SGD","ILDR","LU1868837300.USD","LU2602419157.SGD","FTXH","LU2746668974.SGD","LU2491050154.USD","LU2750360997.AUD","LU1720051108.HKD","LU2023251221.USD","IE00B4R5TH58.HKD","IE00B7KXQ091.USD","LU0006306889.USD","LU0823416689.USD","PJP","LU1267930730.SGD","LU2462157665.USD","XLV","LU0061475181.USD","LU0353189763.USD","THNR","IE0009355771.USD","LU0432979614.USD","LU0820562030.AUD","LU1069344957.HKD","LU0133085943.USD","LU0708995401.HKD","BK4533","GB00BDT5M118.USD","SG9999018865.SGD","LLYZ","LU0683600562.USD","LU2168564149.EUR","LU0689472784.USD","BK4516","LU0471298694.HKD","SG9999014880.SGD","LU2746668461.USD","LU2265009873.SGD","IE00BFSS8Q28.SGD","LU0820561818.USD","IE00BJJMRY28.SGD","LU0096364046.USD","LU0109391861.USD","LU2213496289.HKD","LU0198837287.USD","IE00B1BXHZ80.USD","LU0210536198.USD","LU0256863811.USD","IE00BJJMRX11.SGD","IYH","IE00BKDWB100.SGD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160123473","title":"内克塔治疗宣布自2026年9月8日起进入静默期,直至Rezolve-Aa二期B阶段研究数据公布——源自SEC申报文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1160123473","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160123473?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:14","pubTimestamp":1788898450,"startTime":"0","endTime":"0","summary":"内克塔治疗近日通过美国证券交易委员会的申报文件披露,公司计划自2026年9月8日起步入一段静默期。这一特殊阶段将持续运作,直至备受关注的Rezolve-Aa二期B阶段临床试验数据正式对外揭晓。从具体时间节点来看,9月8日这一天成为了分水岭,此后内克塔治疗将限制对外发表可能影响市场预期的评论或数据。业界分析人士指出,Rezolve-Aa研究的结果对于内克塔治疗而言意义重大,可能直接影响其后续研发管线布局及市场估值走向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165480159","title":"内克塔治疗宣布Rezolve-Ad研究达标:Rezpegaldesleukin 24 μg/kg每两周方案全面实现主要及关键次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1165480159","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165480159?lang=zh_cn&edition=full","pubTime":"2026-08-25 20:31","pubTimestamp":1787661073,"startTime":"0","endTime":"0","summary":"内克塔治疗公司传来重磅消息——其Rezolve-Ad临床研究取得了令人瞩目的成果。该研究针对rezpegaldesleukin 24 μg/kg每两周一次的给药方案,现已达成所有主要终点和关键次要终点。Rezolve-Ad研究的全面成功,不仅验证了rezpegaldesleukin的药理活性,更为后续开发奠定了坚实基础。随着这些积极数据的公布,内克塔治疗在免疫学领域的布局再添重要砝码。rezpegaldesleukin作为备受瞩目的在研药物,其每两周一次24 μg/kg的给药方案若能最终获批,有望为相关疾病患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123088382","title":"财报前瞻|内克塔治疗本季度营收预计小幅下滑,看空观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1123088382","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123088382?lang=zh_cn&edition=full","pubTime":"2026-08-06 09:59","pubTimestamp":1785981549,"startTime":"0","endTime":"0","summary":"内克塔治疗将于2026年08月13日发布财报,市场关注收入承压与费用控制对利润端的影响。市场一致预期显示,内克塔治疗本季度营收预计为1,042.46万美元,同比下降3.91%;调整后每股收益预计为-1.99美元,同比变动34.61%;息税前利润预计为-5,373.57万美元,同比下降39.35%。本季度市场预计营收1,042.46万美元,较上年同期小幅下滑,说明现有版税来源未显著扩张。依据近半年公开报道的分析师及机构评论,对内克塔治疗的最新季度取向整体偏谨慎,看空观点占比较高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻|内克塔治疗本季度营收预计小幅下滑,看空观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119586580","title":"内克塔治疗:三期关键顶线数据预计2028年中出炉,生物制品许可申请目标锁定2029年","url":"https://stock-news.laohu8.com/highlight/detail?id=1119586580","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119586580?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:01","pubTimestamp":1784631697,"startTime":"0","endTime":"0","summary":"内克塔治疗公司宣布,其三期临床试验的初步关键顶线数据预计将于2028年中期获得。该公司已将相关产品的生物制品许可申请目标时间定在2029年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158852357","title":"内克塔治疗启动Zenith AD三期项目,评估新型调节性T细胞生物制剂Rezpegaldesleukin用于中重度特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1158852357","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158852357?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:01","pubTimestamp":1784631693,"startTime":"0","endTime":"0","summary":"内克塔治疗公司宣布,正式启动其名为“Zenith AD”的三期临床项目。该项目旨在评估其新型调节性T细胞生物制剂Rezpegaldesleukin,用于治疗中重度特应性皮炎患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518278576","title":"内克塔治疗盘中异动 股价大跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518278576?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613473,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分,内克塔治疗股票出现异动,股价急速下跌5.25%。截至发稿,该股报0.832美元/股,成交量8612股,换手率0.00%,振幅0.00%。机构评级方面,在所有9家参与评级的机构中,44%的券商给予买入建议,44%的券商给予持有建议,12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.59%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021311398a29c97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021311398a29c97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517416256","title":"内克塔治疗盘中异动 股价大涨5.06%报0.901美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517416256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517416256?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:01","pubTimestamp":1741276885,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时01分,内克塔治疗股票出现波动,股价快速上涨5.06%。截至发稿,该股报0.901美元/股,成交量26.0674万股,换手率0.14%,振幅9.76%。机构评级方面,在所有8家参与评级的机构中,50%的券商给予买入建议,50%的券商给予持有建议,无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.47%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000126989ec59a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000126989ec59a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517602474","title":"内克塔治疗盘中异动 股价大涨5.45%报0.846美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517602474","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517602474?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:59","pubTimestamp":1741111142,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日01时59分,内克塔治疗股票出现异动,股价急速上涨5.45%。截至发稿,该股报0.846美元/股,成交量79.266万股,换手率0.43%,振幅8.90%。机构评级方面,在所有8家参与评级的机构中,50%的券商给予买入建议,50%的券商给予持有建议,无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.35%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015903abe828f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015903abe828f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516744543","title":"内克塔治疗盘中异动 快速拉升5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516744543","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516744543?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:53","pubTimestamp":1740761596,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时53分,内克塔治疗股票出现异动,股价大幅上涨5.15%。截至发稿,该股报0.837美元/股,成交量36.4781万股,换手率0.20%,振幅7.33%。机构评级方面,在所有8家参与评级的机构中,50%的券商给予买入建议,50%的券商给予持有建议,无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.47%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301005316abe10c02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301005316abe10c02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385612","title":"内克塔治疗盘中异动 急速上涨6.36%报0.830美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385612","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385612?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666680,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分,内克塔治疗股票出现波动,股价快速拉升6.36%。截至发稿,该股报0.830美元/股,成交量2.2083万股,换手率0.01%,振幅7.64%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.06%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223120abdf6e75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223120abdf6e75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514522098","title":"内克塔治疗盘中异动 早盘股价大跌5.00%报0.827美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514522098","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514522098?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:59","pubTimestamp":1740585583,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时59分,内克塔治疗股票出现异动,股价大幅下挫5.00%。截至发稿,该股报0.827美元/股,成交量84.9661万股,换手率0.46%,振幅9.99%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.07%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226235943a2550bd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226235943a2550bd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514013834","title":"内克塔治疗盘中异动 早盘急速下跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514013834","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514013834?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:37","pubTimestamp":1740494269,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时37分,内克塔治疗股票出现波动,股价快速下跌5.11%。截至发稿,该股报0.802美元/股,成交量18.7127万股,换手率0.10%,振幅5.12%。机构评级方面,在所有9家参与评级的机构中,44%的券商给予买入建议,44%的券商给予持有建议,12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.09%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223750a25388af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223750a25388af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513786037","title":"内克塔治疗盘中异动 快速下跌5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513786037","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513786037?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:08","pubTimestamp":1740409739,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时08分,内克塔治疗股票出现异动,股价大幅下挫5.39%。截至发稿,该股报0.882美元/股,成交量45.206万股,换手率0.25%,振幅6.53%。机构评级方面,在所有9家参与评级的机构中,44%的券商给予买入建议,44%的券商给予持有建议,12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.64%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230900a2521ddd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230900a2521ddd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512833644","title":"内克塔治疗盘中异动 早盘快速下挫5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512833644","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512833644?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:42","pubTimestamp":1739976163,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时42分,内克塔治疗股票出现波动,股价急速下跌5.19%。截至发稿,该股报1.01美元/股,成交量28.3363万股,换手率0.15%,振幅3.08%。机构评级方面,在所有9家参与评级的机构中,44%的券商给予买入建议,44%的券商给予持有建议,12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.21%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219224244988b3395&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219224244988b3395&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512198046","title":"内克塔治疗盘中异动 股价大涨5.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512198046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512198046?lang=zh_cn&edition=full","pubTime":"2025-02-19 01:47","pubTimestamp":1739900842,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日01时47分,内克塔治疗股票出现波动,股价急速拉升5.84%。截至发稿,该股报1.040美元/股,成交量186.82万股,换手率1.01%,振幅5.96%。机构评级方面,在所有9家参与评级的机构中,44%的券商给予买入建议,44%的券商给予持有建议,12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.64%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219014722988a1d08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219014722988a1d08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511913556","title":"内克塔治疗盘中异动 急速上涨5.38%报0.940美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511913556","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511913556?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:47","pubTimestamp":1739544456,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时47分,内克塔治疗股票出现异动,股价大幅上涨5.38%。截至发稿,该股报0.940美元/股,成交量80.9864万股,换手率0.44%,振幅3.89%。机构评级方面,在所有9家参与评级的机构中,44%的券商给予买入建议,44%的券商给予持有建议,12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.23%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422473696231f39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422473696231f39&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511525746","title":"内克塔治疗盘中异动 早盘急速拉升9.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511525746","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511525746?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:38","pubTimestamp":1739457485,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时38分,内克塔治疗股票出现异动,股价快速拉升9.37%。截至发稿,该股报0.800美元/股,成交量58.255万股,换手率0.32%,振幅6.01%。机构评级方面,在所有9家参与评级的机构中,44%的券商给予买入建议,44%的券商给予持有建议,12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.21%。内克塔治疗公司简介:Nektar Therapeutics 是一家制药公司,专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213223805abcdb370&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213223805abcdb370&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.0495},{"period":"1month","weight":0.0036},{"period":"3month","weight":-0.528},{"period":"6month","weight":-0.4764},{"period":"1year","weight":-0.3973},{"period":"ytd","weight":-0.1507}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0404},{"period":"3month","weight":-0.0476},{"period":"6month","weight":-0.0138},{"period":"1year","weight":0.1003},{"period":"ytd","weight":0.0741}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nektar Therapeutics于1990年在加州成立,并于1998年重新在特拉华州注册。该公司是一家临床阶段、研究型药物发现生物制药公司,专注于发现和开发免疫治疗领域的创新药物。在这个不断增长的领域内,该公司致力于创造新的免疫调节剂,选择性地诱导、放大、减弱或阻止免疫反应,以达到预期的治疗效果。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.029488},{"month":3,"riseRate":0.40625,"avgChangeRate":-0.000642},{"month":4,"riseRate":0.46875,"avgChangeRate":0.016904},{"month":5,"riseRate":0.34375,"avgChangeRate":-0.004399},{"month":6,"riseRate":0.424242,"avgChangeRate":0.026471},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.018591},{"month":8,"riseRate":0.484848,"avgChangeRate":0.043831},{"month":9,"riseRate":0.484848,"avgChangeRate":0.036592},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.033431},{"month":11,"riseRate":0.666667,"avgChangeRate":0.08218},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"内克塔治疗","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"内克塔治疗,NKTR,内克塔治疗股票,内克塔治疗股票老虎,内克塔治疗股票老虎国际,内克塔治疗行情,内克塔治疗股票行情,内克塔治疗股价,内克塔治疗股市,内克塔治疗股票价格,内克塔治疗股票交易,内克塔治疗股票购买,内克塔治疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}